About this data
Anyone paid to communicate with the Texas Legislature or a state agency to influence legislation or administrative action must register as a lobbyist with the Texas Ethics Commission. Each registration lists the lobbyist's clients and the subject areas they work on. Compensation is a self-reported bracket, not an exact figure, and a payment type of “prospective” means the lobbyist has registered but reported no compensation yet. Registration is with a branch of government — it does not indicate contact with, or support from, any specific officeholder.
2026 registration
| Client | Compensation | Type | Period |
|---|---|---|---|
| Acadia Pharmaceuticals | $23K–$57K | Prospective — no compensation reported yet | Jan 1, 2026 → Dec 31, 2026 |
| Cystic Fibrosis Foundation | $23K–$57K | Prospective — no compensation reported yet | Jan 1, 2026 → Dec 31, 2026 |
| Dexcom | $23K–$57K | Prospective — no compensation reported yet | Jan 1, 2026 → Dec 31, 2026 |
| NewLight Healthcare | $23K–$57K | Prospective — no compensation reported yet | Jan 1, 2026 → Dec 31, 2026 |
| Roche Diagnostics | $23K–$57K | Prospective — no compensation reported yet | Jan 1, 2026 → Dec 31, 2026 |
| Solventum | $23K–$57K | Prospective — no compensation reported yet | Jan 1, 2026 → Dec 31, 2026 |
| Vertex Pharmaceuticals Inc. | $57K–$114K | Prospective — no compensation reported yet | Jan 1, 2026 → Dec 31, 2026 |
Subject areas
Health And Health Care
2024 registration
| Client | Compensation | Type | Period |
|---|---|---|---|
| 3M Company | $22K–$54K | Prospective — no compensation reported yet | Jan 1, 2024 → Dec 31, 2024 |
| Vimo, Inc | $22K–$54K | Prospective — no compensation reported yet | Jan 1, 2024 → Dec 31, 2024 |
| Acadia Pharmaceuticals | $22K–$54K | Prospective — no compensation reported yet | Jan 1, 2024 → Dec 31, 2024 |
| Cystic Fibrosis Foundation | $22K–$54K | Prospective — no compensation reported yet | Jan 1, 2024 → Dec 31, 2024 |
| Dexcom | $22K–$54K | Prospective — no compensation reported yet | Jan 1, 2024 → Dec 31, 2024 |
| NewLight Healthcare | $22K–$54K | Prospective — no compensation reported yet | Jan 1, 2024 → Dec 31, 2024 |
| Roche Diagnostics | $0–$22K | Prospective — no compensation reported yet | Jan 1, 2024 → Dec 31, 2024 |
| Vertex Pharmaceuticals Inc. | $54K–$108K | Prospective — no compensation reported yet | Jan 1, 2024 → Dec 31, 2024 |
Subject areas
Health And Health Care